Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 20INDUSTRY 6NIH 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Sarcoma 1Myeloid 1

Conditions

Hyperuricemia 3Tumor Lysis Syndrome 2Lymphoma 2Leukemia 2Sarcoma, Alveolar Soft Part 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Inflammation 1Gout 1Chondrosarcoma 1Cardiovascular Diseases 1Arthritis 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Allopurinol × Clear all
NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 1/2 Terminated
178 enrolled 33 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT00401388 2018-03-07

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

AEterna Zentaris

Phase 2 Completed
72 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Alveolar Soft Part

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated
10 enrolled

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡